Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 3/2010

01.12.2010 | Case Report

Case report: long-term outcome post-heart transplantation in a woman with Fabry’s disease

verfasst von: Flavia Verocai, Joe Thomas Clarke, Robert M. Iwanochko

Erschienen in: Journal of Inherited Metabolic Disease | Sonderheft 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Fabry’s disease is an X-linked recessive disorder that results from the deficiency of alpha-galactosidase A and causes the accumulation of globotriaosylceramide (Gb3) in different tissues. It leads to a rare form of cardiomyopathy which may be complicated by end-stage heart failure and need to heart transplant. Our group described the first case of heart transplant in a woman with cardiomyopathy secondary to Fabry’s disease about 12 years ago. There was uncertainty in regards to the possibility of recurrence of the disease as previously documented in kidney transplant recipients and long-term outcomes. In this report, 14 years after transplant, this woman is still alive and there is no evidence of Fabry’s disease in any of the endomyocardial biopsies. Heart transplantation can be recommended for Fabry’s patients with end-stage cardiomyopathy.
Literatur
Zurück zum Zitat Pierre-Louis B, Kumar A, Frishman WH (2009) Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev 17:31–35PubMedCrossRef Pierre-Louis B, Kumar A, Frishman WH (2009) Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev 17:31–35PubMedCrossRef
Zurück zum Zitat Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93(4):528–535PubMedCrossRef Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93(4):528–535PubMedCrossRef
Zurück zum Zitat Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047–1053PubMedCrossRef Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047–1053PubMedCrossRef
Zurück zum Zitat Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50–59PubMedCrossRef Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50–59PubMedCrossRef
Zurück zum Zitat Cecchi F, Frullini A, Olivotto I, Castelli G, Ciaccheri M, Martinelli F, Torricelli F, Borsini W, Garbini F (2007) Hypertrophic cardiomyopathy in Anderson-Fabry disease. Clin Ther 29(Suppl C):S93–S94CrossRef Cecchi F, Frullini A, Olivotto I, Castelli G, Ciaccheri M, Martinelli F, Torricelli F, Borsini W, Garbini F (2007) Hypertrophic cardiomyopathy in Anderson-Fabry disease. Clin Ther 29(Suppl C):S93–S94CrossRef
Zurück zum Zitat Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP (2008) Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet and Metabol 93(2):112–128CrossRef Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP (2008) Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet and Metabol 93(2):112–128CrossRef
Zurück zum Zitat Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K, Barr M (2006) Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006. J Heart Lung Transplant 25(9):1024–1042PubMedCrossRef Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K, Barr M (2006) Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006. J Heart Lung Transplant 25(9):1024–1042PubMedCrossRef
Zurück zum Zitat Cantor WJ, Daly P, Iwanochko M, Clarke JTR, Cusimano RJ, Butany J (1998) Cadiac transplantation for Fabry’s disease. Can J Cardiol 14(1):81–84PubMed Cantor WJ, Daly P, Iwanochko M, Clarke JTR, Cusimano RJ, Butany J (1998) Cadiac transplantation for Fabry’s disease. Can J Cardiol 14(1):81–84PubMed
Zurück zum Zitat Kleinert K, Kotanko P, Spada M, Pagliardini S, Paschke E, Paul K, Voigtlander T, Wallner M, Kramar R, Stummvoll HK, Schwarz C, Horn S, Holzer H, Fodinger M, Sunder-Plassmann G (2009) Anderson–Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 22(3):287–292PubMedCrossRef Kleinert K, Kotanko P, Spada M, Pagliardini S, Paschke E, Paul K, Voigtlander T, Wallner M, Kramar R, Stummvoll HK, Schwarz C, Horn S, Holzer H, Fodinger M, Sunder-Plassmann G (2009) Anderson–Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 22(3):287–292PubMedCrossRef
Zurück zum Zitat Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G, European FOS Investigators Group (2009) Kidney transplantation in patients with Fabry disease. Transpl Int 22(4):475–481PubMedCrossRef Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G, European FOS Investigators Group (2009) Kidney transplantation in patients with Fabry disease. Transpl Int 22(4):475–481PubMedCrossRef
Zurück zum Zitat Karras A, De Lentdecker P, Delahousse M, Debauchez M, Tricot L, Pastural M, Bruneval P, Zemoura L, Van Huyen DJ, Lidove O (2008) Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era. Am J Transplant 8:1345–1348PubMedCrossRef Karras A, De Lentdecker P, Delahousse M, Debauchez M, Tricot L, Pastural M, Bruneval P, Zemoura L, Van Huyen DJ, Lidove O (2008) Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era. Am J Transplant 8:1345–1348PubMedCrossRef
Zurück zum Zitat Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Mehta AB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153–158PubMedCrossRef Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Mehta AB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153–158PubMedCrossRef
Zurück zum Zitat Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216–1221PubMedCrossRef Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216–1221PubMedCrossRef
Zurück zum Zitat Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J (2009) Long-term rffects of rnzyme replacement therapy on Fabry cardiomyopathy evidence for a better outcome with early rreatment. Circulation 119:524–529PubMedCrossRef Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J (2009) Long-term rffects of rnzyme replacement therapy on Fabry cardiomyopathy evidence for a better outcome with early rreatment. Circulation 119:524–529PubMedCrossRef
Zurück zum Zitat Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT (2009) Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374(9706):1986–1996PubMedCrossRef Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT (2009) Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374(9706):1986–1996PubMedCrossRef
Zurück zum Zitat Weidemann F, Linhart A, Monserrat L, Strotmann J (2010) Cardiac challenges in patients with Fabry disease. Int J Cardiol 141(1):3–10PubMedCrossRef Weidemann F, Linhart A, Monserrat L, Strotmann J (2010) Cardiac challenges in patients with Fabry disease. Int J Cardiol 141(1):3–10PubMedCrossRef
Metadaten
Titel
Case report: long-term outcome post-heart transplantation in a woman with Fabry’s disease
verfasst von
Flavia Verocai
Joe Thomas Clarke
Robert M. Iwanochko
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe Sonderheft 3/2010
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9194-3

Weitere Artikel der Sonderheft 3/2010

Journal of Inherited Metabolic Disease 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.